PHLDA2 Antibody | 15-268

PHLDA2 Antibody | 15-268 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Rat

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-152 of human PHLDA2 (NP_003302.1) .

Research Area: Apoptosis, Cancer, Cell Cycle

Tested Application: WB, IHC

Application: WB: 1:500 - 1:2000
IHC: 1:50 - 1:200

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: PHLDA2, pleckstrin homology-like domain, family A, member 2, TSSC3, IPL, BRW1C, BWR1C, HLDA2, PHLDA2, tumor suppressing subtransferable candidate 3, tumor-supressing STF cDNA 3, imprinted in placenta and liver, p17-Beckwith-Wiedemann region 1C, pleckstrin homology-like domain family A member 2, tumor suppressing subchromosomal transferable fragment cDNA 3

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: This gene is located in a cluster of imprinted genes on chromosome 11p15.5, which is considered to be an important tumor suppressor gene region. Alterations in this region may be associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. This gene has been shown to be imprinted, with preferential expression from the maternal allele in placenta and liver.